Sickle Cell Anemia: Modern Trends in Treatment

Intsar S. Waked and Amal A. Alotaibi
College of Applied Medical Sciences, Majmaah University, Kingdom of Saudi Arabia

Series: Recent Advances in Hematology Research, Physical Medicine and Rehabilitation
BISAC: MED038000



Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick


Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:



Sickle cell disease (SCD), an inherited hemolytic anemia, is associated with multiple acute and chronic complications such as painful vasoocclusive events, cerebral vasculopathy, priapism, and renal or lung disease. These complications are variable and unpredictable, and can be associated with significant morbidity and poor quality of life. This book covers several areas regarding pathology, diagnosis, complications, signs, symptoms and medical treatments. There are few studies in literature on the role of physiotherapy as a resource to prevent and treat locomotor system disorders, respiratory problems and painful crises in SCD individuals. This book highlights the role of physiotherapy in sickle cell anemia.

A comprehensive and authoritative monograph, this book will be equally interesting to both established researchers and to graduate students interested in both genetics and the physical therapy field. (Imprint: Nova Biomedical)



Definition of Terms

Chapter 1. Epidemiology and Distribution

Chapter 2. Anatomy and Physiology

Chapter 3. Genetic Inheritance

Chapter 4. Pathophysiology of SCD

Chapter 5. Diagnosis of SCA

Chapter 6. Signs and Symptoms of Sickle Cell Anemia

Chapter 7. Sickle Cell Diseases Complications

Chapter 8. Imaging of SCA

Chapter 9. Prevention and Treatment of Sickle Cell Anemia

Chapter 10. Role of Physical Therapy in the Treatment of Sickle Cell Anemia


About the Authors


[1] Schnog JB, Duits AJ,Muskiet FA, ten Cate H, Rojer RA, Brandjes DP. Sickle cell disease; a general overview. Neth J Med 2004;62:364–74.
[2] Claster S, Vichinsky EP. Managing sickle cell disease. BMJ 2003;327:1151–5.
[3] Modell B, Darlison M. Global epidemiology of hemoglobin disorders and derived service indicators. Bull World Health Organ 2008;86:480–7.
[4] Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010;115:4331–6.
[5] Buchanan G, Vichinsky E, Krishnamurti L, Shenoy S. Severe sickle cell disease pathophysiology and therapy. Biol Blood Marrow Transplant 2010;16:S64–7.
[6] Therrell BL, HannonWH. National evaluation of US newborn screening system components. Ment Retard Dev Disabil Res Rev 2006;12:236–45.
[7] Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol 2010;85:77–8.
[8] Rees David C, Williams Thomas N, Gladwi Mark T. Sickle-cell disease. Lancet 2010;376:2018–31.
[9] Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997;337:762–9.
[10] Santos MN, Bezerra MA, Domingues BL, Zaccariotto TR, Oliveira DM, Costa FF, et al. Genet Test Mol Biomarkers 2011;15(10):709–13.
[11] Ejindu Vivian C, Hine Andrew L, Mashayekhi Mohammad, Shorvon Philip J, Misra Rakesh R. Musculoskeletal manifestations.
[12] World Health Organization (1989) Meeting the Needs of people with Hemoglobin Disorder. Geneva: WHO.
[13] Franklyn, I. (1990) Sickle Cell Disease: A Guide for Patients, Carers and Health Workers. London.
[14] Bloom, M. (1996) Sickle Cell Disease. Berkeley CA: Roundhouse Publishing.
[15] Karlsson, S. The first steps on the gene therapy pathway to anti-sickling success. Nature Medicine 6, 139-140, 2000.
[16] Blouin, M.-J., Beauchemin, H., Wright, A., De Paepe, M., Sorette, M., Bleau, A.-M., Nakamoto, B., Ou, C.-N., Stamatoyannopoulos, G., and Trudel, M. Genetic correction of sickle cell disease: Insights using transgenic mouse models. Nature Medicine 6, 177-182.
[17] Keeton, W., and J. Gould. Biological Science, W.W. Norton and Co., NY, NY, 1986.
[18] Leary, W. Sickle Cell Trial Called Success, Halted Early, NY Times, January 31, 1995. pp. B5, B8.
[19] Lewis, R. Human Genetics: Concepts and Applications, 3rd ed., pp. 334-335, WCB/McGraw-Hill, Boston, 1999.
[20] Lewis, R. Case Workbook in Human Genetics, pp. 113-114, Wm C. Brown Publishers, Dubuque, IA, 1994.
[21] Serjeant, G.R., Serjeant, B.E. (2001) Sickle Cell Disease. Oxford: Oxford University Press.
[22] Pauling L, Itano H, Singer SJ, Wells IC. Sickle cell anemia: a molecular disease. Science. 1949;110:543–8.
[23] Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anemia hemoglobin. Nature. 1956;178:792–4.
[24] Bunn H, Forget BG. Hemoglobin: Molecular, genetic and clinical aspects. Philadelphia, PA, USA: WB Saunders; 1986.
[25] Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337:762–9.
[26] Edelstein SJ, Telford JN, Crépeau RH. Structure of fibers of sickle cell hemoglobin. Proc Natl Acad Sci USA. 1973;70:1104–7.
[27] Schnog JB, Duits AJ, Muskiet FA, ten Cate H, Rojer RA, Brandjes DP. Sickle cell disease; a general overview. Neth J Med 2004; 62: 362-74.
[28] Labie D, Elion J. Molecular and cellular pathophysiology of sickle cell anemia. Pathol Biol (Paris)1999;47:7–12.
[29] MJ, Nagel RL. Sickle-cell disease. Lancet. 2004;364:1343–60.
[30] Elion J, Labie D. Bases physiopathologiques moléculaires et cellulaires du traitement de la drépanocytose. Hématologie. 1996;2:499–510.
[31] Hebbel RP, Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest. 1997 Dec 1; 100(11 Suppl):S83-6.
[32] Mohandas N, Evans E, Adherence of sickle erythrocytes to vascular endothelial cells: requirement for both cell membrane changes and plasma factors. Blood. 1984 Jul; 64(1):282-7.
[33] Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP, Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 1997 Nov 27; 337(22):1584-90.
[34] El Nemer W, Colin Y, Le Van Kim C, Role of Lu/BCAM glycoproteins in red cell diseases. Transfus Clin Biol. 2010 Sep; 17(3):143-7.
[35] Marie-Hélène Odièvre, Emmanuelle Verger, Ana Cristina Silva-Pinto, and Jacques Elion Pathophysiological insights in sickle cell disease. Indian J Med Res. 2011 Oct; 134(4): 532–537.
[36] Chiang EY, Frenette PS. Sickle cell vaso-occlusion. Hematol Oncol Clin North Am. 2005;9:771–94.
[37] Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest. 2007;117:850–8.
[38] Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639–44.
[39] Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106:411–20.
[40] Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 2004;11:129–51.
[41] Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007;21:157–71.
[42] Rivera A, Jarolim P, Brugnara C. Modulation of Gardos channel activity by cytokines in sickle erythrocytes. Blood. 2002;99:357–603.
[43] Merciris P, Giraud F. How do sickle cells become dehydrated? Hematol J. 2001;2:200–5.
[44] Durpès MC1, Nebor D, du Mesnil PC, Mougenel D, Decastel M, Elion J, et al. Effect of interleukin-8 and RANTES on the Gardos channel activity in sickle human red blood cells: role of the Duffy antigen receptor for chemokines. Blood Cells Mol Dis. 2010;44:219–23.
[45] El Nemer W, Colin Y, Le Van Kim C. Role of Lu/BCAM glycoproteins in red cell diseases. Transfus Clin Biol. 2010;17:143–7.
[46] Hines PC1, Zen Q, Burney SN, Shea DA, Ataga KI, Orringer EP, Telen MJ, Parise LV.. Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. Blood. 2003;101:3281–7.
[47] Kato GJ1, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21:37–47.
[48] Reiter CD, Gladwin MT. An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol. 2003;10:99–107.
[49] Morris CR1, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA. 2005;294:81–90.
[50] Mack AK, Kato GJ. Sickle cell disease and nitric oxide: a paradigm shift? Int J Biochem Cell Biol. 2006;38:1237–43.
[51] Hebbel RP, Mohandas N. Sickle cell adherence. In Embury SH, Hebbel RP, Mohandas N, Steinburg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. New York: Raven Press; 1994.
[52] Embury SH, Hebbel RP, Steinberg MH, Mohandas N. Pathogenesis of vasoocclusion. In: Embury SH, Hebbel RP, Mohandas N, Steinburg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. New York: Raven Press; 1994.
[53] Nash, GB, Johnson CS, Meiselman HJ. Mechanical properties of oxygenated red blood cells in sickle cell (HbSS) disease. Blood. 1984;63:73-80.
[54] Clark MFR, Mohandas N, Shohet SB. Deformability of oxygenated irreversibly sickled cells. J Clin Invest. 1980;65:189-196.
[55] Schmalzer EA, Manning RS, Chien S. Filtration of sickle cells: recruitment into a rigid fraction as a function of density and oxygen tension. J Lab Clin Med. 1989;113:727-734.
[56] Mackie LH, Hochmuth RM. The influence of oxygen tension, temperature and hemoglobin concentration on the rheoloical properties of sickle erythrocytes. Blood. 1990;76:1256-1261.
[57] Drasler WJ, Smith CM, 2nd, Keller KH. Viscoelastic properties of the oxygenated sickle erythrocyte membrane. Biorheology. 1989;26(5):935–949.
[58] Nash GB, Johnson CS, Meiselman HJ. Influence of oxygen tension on the viscoelastic behavior of red blood cells in sickle cell disease. Blood. 1986;67:110-118.
[59] Kaul DK, Xue H. Rate of deoxygenation and rheologic behavior of blood in sickle cell anemia. Blood. 1991;77:1353-1361.
[60] Chien S, Usami S, Bertles JF. Abnormal rheology of oxygenated blood in sickle cell anemia. J Clin Invest. 1970;49:623-634.
[61] Schmalzer EA, Lee JO, Brown AK, et al. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion. Transfusion. 1987;27:228-233.
[62] Midence, K., Elander, J. (1994) Sickle Cell Disease: A Psychosocial Approach. Oxford: Radcliffe Medical Press.
[63] Lashwood, A. (2002) Pre-implantation genetic diagnosis for sickle cell disease. Sickle Cell News Review. Winter Edition. London: Sickle Cell Society.
[64] Anionwu, E., Jibril, H. (1986) Sickle Cell Disease: A Guide for Families. London: Longman.
[65] Oni, L. et al. (1997) Care and Management of your Child with Sickle Cell Disease: A Parent’s Guide. London: Health First Graphic Design Studio.
[66] Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-44.
[67] Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79(1):17-25.
[68] Booth C, Inusa B, Obaro SK. Infection in sickle cell disease: a review. Int J Infect Dis. 2010;14(1):e2-e12.
[69] Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288- 94.
[70] Verduzco LA, Nathan DG. Sickle cell disease and stroke. Blood. 2009;114(25):5117-25.
[71] Morris CR. Asthma management: reinventing the wheel in sickle cell disease. Am J Hematol 2009;84:234–41.
[72] Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with increased mortality in individuals with sickle cell anemia. Haematologica 2007;92:1115–8.
[73] Pham PT, Pham PC, Wilkinson AH, Lew SQ. Renal abnormalities in sickle cell disease. Kidney Int. 2000;57(1):1-8.
[74] Shao SH, Orringer EP. Sickle cell intrahepatic cholestasis: approach to a difficult problem. Am J Gastroenterol. 1995; 90(11):2048-50.
[75] Smith-Whitley K, Zhao H, Hodinka RL, Kwiatkowski J, Cecil R, Cecil T, et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood. 2004;103(2):422-7.
[76] Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342(25):1855- 65.
[77] Olujohungbe AB, Adeyoju A, Yardumian A, Akinyanju O, Morris J, Westerdale N, et al. A prospective diary study of stuttering priapism in adolescents and young men with sickle cell anemia: report of an international randomized control trial—The Priapism in Sickle Cell Study. J Androl. 2011;32(4):375-82.
[78] Hassell KL, Eckman JR, Lane PA. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. Am J Med. 1994;96(2):155- 62.
[79] Serjeant DR, Serjeant BE. Sickle cell disease. New York: Oxford University Press; 2001
[80] Diggs LW. Bone and joint lesions in sickle-cell disease. Clin Orthop Relat Res. 1967;52:119- 43
[81] Mason VR. Sickle cell anemia. J Am Med Assoc. 1922; 79:1318-20.
[82] Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S55-66.
[83] Ataga KI, Orringer EP. Renal abnormalities in sickle cell disease. Am J Hematol. 2000;63(4):205-11.
[84] Francis YF, Worthen HG. Hyposthenuria in sickle cell disease. J Natl Med Assoc. 1968;60(4):266-70.
[85] Moriarty BJ, Acheson RW, Condon PI, Serjeant GR. Patterns of visual loss in untreated sickle cell retinopathy. Eye (Lond). 1988;2 (Pt 3):330-5.
[86] Schnog JB, Duits AJ,Muskiet FA, ten Cate H, Rojer RA, Brandjes DP. Sickle cell disease; a general overview. Neth J Med 2004; 62:364–74.
[87] Claster S, Vichinsky EP. Managing sickle cell disease. BMJ 2003; 327:1151–5.
[88] Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes Jr J, et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol 2003;123:359–65.
[89] Vichinsky EP, Styles LA, Colangelo LH,Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 1997;89:1787–92.
[90] Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991;325:11–6.
[91] McClish DK, Levenson JL, Penberthy LT, Roseff SD, Bovbjerg VE, Roberts JD, et al. Gender differences in pain and healthcare utilization for adult sickle cell patients: The PiSCES Project. J Womens Health (Larchmt) 2006;15:146–54.
[92] Strouse JJ, Lanzkron S, Urrutia V. The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease. Expert Rev Hematol 2011;4:597–606.
[93] Ejindu Vivian C, Hine Andrew L, Mashayekhi Mohammad, Shorvon Philip J, Misra Rakesh R. Musculoskeletal manifestations manifestations of sickle cell disease. RadioGraphics 2007;7:1005–21.
[94] Ramirez Ivan, Choi Mark HJ, Asrat Welansa, Lederman Henrique M, Coombs Bernard D, Reinus William R, et al. Sickle Cell Anemia Skeletal Imaging 2011,
[95] Ganguly A, Boswell W, Aniq H. Musculoskeletal manifestations of sickle cell anaemia: a pictorial review. Anemia 2011. http://dx.doi.
[96] Gilkeson RC, Basile V, Sands MJ, Hsu JT. Chest case of the day. Extramedullary hematopoiesis (EMH). AJR Am J Roentgenol 1997;169(267):270–3.
[97] Choi Haesun, David Cynthia L, Katz Ruth L, Podoloff Donald A. Case 69: extramedullary hematopoiesis. Radiology 2004;231(1):52–6.
[98] Berkmen Yahya M, Zalta Benjamin A. Case 126: extramedullary hematopoiesis. Radiology 2007;245(3):905–8.
[99] Tsitouridis J, Stamos S, Hassapopoulou E, Tsitouridis K, Nikolopoulos P. Extramedullary paraspinal hematopoiesis in thalassemia: CT and MRI evaluation. Eur J Radiol 1999;30:33–8.
[100] Gumbs1 Edith Roma V, Higginbotham-Ford A, Teal1 Guno James S, Kletter G, Castro Oswald. Thoracic extramedullary hematopoiesis in sickle-cell disease. AJR 1987;149(November): 889–93.
[101] Babhulkar SS, Pande Ketan, Babhulkarb Sushrut. The hand-footsyndrome in sickle-cell. Bone Joint J Bone Joint Surg [Br] 1995;77(-B):310–2.
[102] Almeida Antonio, Roberts Irene. Bone involvement in sickle cell disease. Br J Haematol 2005;129:482–90.
[103] Phatak SV, Kolwadkar PK, Phatak MS. Pictorial essay: radiographic skeletal changes in Sickle cell Anemia. Ind J Radiol Imaging 2006;16(4):627–32.
[104] Bahebeck J, Atangana R, Techa A, Monny-Lobe M, Sosso M, Hoffmeyer P. Relative rates and features of musculoskeletal complications in adult sicklers. Acta Orthop Belg 2004;70:107–11.
[105] Blacksin1 Marcia F, Finzel2 Kathleen C, Benevenia Joseph. Osteomyelitis originating in and around bone infarcts. AJR Am J Roentgenol 2001;176(2):38.
[106] Saito Naoko, Nadgir Rohini N, Flower Elisa N, Sakai Osamu. Clinical and radiologic manifestations of sickle cell disease in the head and neck. Radiographics 2010;30(4):1021–34.
[107] Allison JW, Glasier CM, Stark JE, James CA, Angtuaco EJ. Head and neck MR angiography in pediatric patients: a pictorial essay. Radiographics 1994;14(4):795–805.
[108] Gladwin MarkT, Sachdev Vandana. Cardiovascular Abnormalities in sickle cell disease. J Am Coll Cardiol 2012;59(13):1123–33.
[109] Cheitlin DM, McAllister HA, de Castro CM. Myocardial infarction without atherosclerosis. JAMA 1975;231:951–9.
[110] Saad STO, Arruda VR, Junqueira OOMD, Schelini FA, Coelho OB. Acute myocardial infarction in sickle cell anaemia associated with severe hypoxia. Postgrad Med J 1990; 66:1068–70.
[111] Eugene C. Lin, Evan J. Samett, Justin D. Pearlman, Bernard D. Coombs, et al. Cardiac MRI, Technical Aspects Primer. .
Updated: Apr 20, 2011.
[112] Gorka Bastarrika, Yeong Shyan Lee, Walter Huda, Balazs Ruzsics, Philip Costello, UJoseph Schoepf. CT of coronary artery disease. Radiology 2009;253(2):317–38.
[113] Aaron W. Bernard, Zahida Yasin, Arvind Venkat, M. Acute Chest Syndrome of Sickle Cell Disease. memberfile.php?PubCode=hp_jan07_sickle.pdf>.
[114] Godeau B, Schaeffer A, Bachir D, et al. Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: value for diagnostic assessment of fat embolism. Am J Respir Crit Care Med 1996;153(5):1691–6.
[115] Ademola Emmanuel Fawibe, Philip Manman Kolo, James Ayodele Ogunmodede, Olufemi Olumuyiwa Desalu, Kazeem Alakija Salami. Advanced sickle cell associated interstitial lung disease presenting with cor pulmonale in a Nigerian. Niger Med J 2012;53(2):105–7.
[116] PIatt1 Joel F, Ellis1 James H, Rubin1 Jonathan M, DiPietro, Michael A, Sedman Aileen B. Intrarenal arterial doppler sonography in patients with nonobstructive renal disease: correlation of resistive index with biopsy findings. AJR 1990;154:1223–7.
[117] Platt JF, Rubin JM, Ellis JH, DiPietro M. Duplex Doppler US of the kidney: differentiation of obstructive from non-obstructive dilatation.
[118] Claster S, Vichinsky E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea. Splenic Regeneration 1996;88:1951–3.
[119] Manish Parikh, John Geibel Lewis J. Kaplan, Lewis J. Kaplan, et al. Splenic Infarct Treatment & Management. . Updated: Apr 4, 2012.
[120] Michael R. Federle, R. Brooke Jeffrey, Terry S. Desser, Venkata Sridhar Anne, et al. Vascular disorder Splenic infarct. Diagnostic Imaging Abdomen. PART I GI Tract and Abdominal Cavity. Section 6 Spleen: 373–340; Amirsys 2004.
[121] Morishima Aki, Schofer Joel M, Pelletier Pierre, McKee James M. Images in emergency medicine: splenic infarction due to sickle cell trait after climbing Mt. Fuji. West J Emerg Med 2008;9(3):179.
[122] Behrang Amini. Splenic Abscess after Infarction. roentgenrayreader.>. Thursday, September 9, 2010.
[123] Gauthier N, Cornud F, Vissuzaine C. Liver infarction in sickle cell disease. AJR 1985;144:1089–90, 10.2214/ajr.144.5.1089.
[124] Michael R. Federle, Brooke R. Jeffrey, Terry S. Desser, Venkata Sridhar Anne, et al. Diagnostic Imaging Abdomen. PART II Hepatobiliary and Pancreas. Section 1 Liver: Vascular disorder: Hepatic infarct. 373–340; Amirsys 2004.
[125] Michael R. Federle, R. Brooke Jeffrey, Terry S. Desser, Venkata Sridhar Anne, et al. Diagnostic Imaging Abdomen. PART II Hepatobiliary and Pancreas. Section 1 Liver: Metabolic-Inherited: hemochromatosis. 545–548; Amirsys 2004.
[126] Isabel B. Oliva, Amir H. Davarpanah, Frank J. Rybicki, Karin E. Dill,
et al. Mesenteric Ischemia. American College of Radiology. ACR Appropriateness Criteria.
[127] Dalrymple Neal C, Prasad Srinivasa R, Freckleton Michael W, Chintapalli Kedar N. Informatics in radiology (infoRAD): introduction to the language of three-dimensional imaging with multidetector CT. Radiographics 2005;25(5):1409–28, doi:10.1148/rg.255055044..
[128] Eric H. Krau. Anthony D. Villella. Chronic Conditions of Sickle Cell Anemia. . Jul 10, 2009.
[129] Lewis Hsu, James Eckman. Specific Problems: Sequestration – Spleen or Liver. Sickle cell information center. .
[130] Ahmed S, Siddiqui AK, Siddiqui RK, Kimpo M, Russo L, Mattana. Acute pancreatitis during sickle cell vaso-occlusive painful crisis. J Am J Hematol 2003;73(3):190–3.
[131] Julka RN, Aduli F, Lamps LW, Olden KW. Ischemic duodenal ulcer, an unusual presentation of sickle cell disease. J Natl Med Assoc 2008;100(3):339–41.
[132] Stewart CL, Me´nard GE. Sickle cell-induced ischemic colitis. J Natl Med Assoc 2009;101(7):726–8.
[133] d’Almeida Maria, Jose Jean, Oneto Julieta, Restrepo Ricardo. Bowel wall thickening in children: CT findings. Radiographics 2008;28(3):727–46,
[134] Amrolia PJ, Almeida A, Halsey C, et al. Therapeutic challenges in childhood sickle cell disease. Part 1: current and future treatment options. Br J Haematol 2003; 120:725.
[135] Wang CJ, Kavanagh PL, Little AA, et al. Quality-of-Care Indicators for Children With Sickle Cell Disease. Pediatrics 2011; 128:484.
[136] Woods KF, Johnson JA, Kutlar A, et al. Sickle cell disease telemedicine network for rural outreach. J Telemed Telecare 2000; 6:285.
[137] Patik M, Phillips L, Kladny B, et al. Structured telephone-based outreach using nonmedical personnel can improve adherence to comprehensive care in families of children with sickle cell disease. Am J Hematol 2006; 81:462.
[138] Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033.
[139] Wong WY, Overturf GD, Powars DR. Infection caused by Streptococcus pneumoniae in children with sickle cell disease: epidemiology, immunologic mechanisms, prophylaxis, and vaccination. Clin Infect Dis 1992; 14:1124.
[140] Vernacchio L, Neufeld EJ, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998; 133:275.
[141] Marcinak JF, Frank AL, Labotka RL, et al. Immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in 3- to 17-month-old infants with sickle cell diseases. J Pediatr 1991; 118:69.
[142] Bjornson AB, Falletta JM, Verter JI, et al. Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. J Pediatr 1996; 129:828.
[143] Strouse JJ, Reller ME, Bundy DG, et al. Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease. Blood 2010; 116:3431.
[144] Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44:1428.
[145] Lederman HM, Connolly MA, Kalpatthi R, et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics 2014; 134:686.
[146] Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics 2008; 121:562.
[147] Section on Hematology/Oncology Committee on Genetics, American Academy of Pediatrics. Health supervision for children with sickle cell disease. Pediatrics 2002; 109:526.
[148] Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:258.
[149] American Academy of Pediatrics. Pneumococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th Ed, Pickering LK, Baker CJ, Kimberlin DW, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.571.
[150] ( (Accessed on January 07, 2013).
[151] Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr 1995; 127:685.
[152] Bundy DG, Strouse JJ, Casella JF, Miller MR. Burden of influenza-related hospitalizations among children with sickle cell disease. Pediatrics 2010; 125:234.
[153] American Academy of Pediatrics. Immunization in special clinical circumstances. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove, Il 2015. p.68.
[154] Wong WY, Powars DR, Chan L, et al. Polysaccharide encapsulated bacterial infection in sickle cell anemia: a thirty year epidemiologic experience. Am J Hematol 1992; 39:176.
[155] McCavit TL, Gilbert M, Buchanan GR. Prophylactic penicillin after 5 years of age in patients with sickle cell disease: a survey of sickle cell disease experts. Pediatr Blood Cancer 2013; 60:935.
[156] Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986; 314:1593.
[157] John AB, Ramlal A, Jackson H, et al. Prevention of pneumococcal infection in children with homozygous sickle cell disease. Br Med J (Clin Res Ed) 1984; 288:1567.
[158] Riddington C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev 2002; CD003427.
[159] McCavit TL, Quinn CT, Techasaensiri C, Rogers ZR. Increase in invasive Streptococcus pneumoniae infections in children with sickle cell disease since pneumococcal conjugate vaccine licensure. J Pediatr 2011; 158:505.
[160] Buchanan GR, Smith SJ. Pneumococcal septicemia despite pneumococcal vaccine and prescription of penicillin prophylaxis in children with sickle cell anemia. Am J Dis Child 1986; 140:428.
[161] Ellison AM, Ota KV, McGowan KL, Smith-Whitley K. Pneumococcal bacteremia in a vaccinated pediatric sickle cell disease population. Pediatr Infect Dis J 2012; 31:534.
[162] Sox CM, Cooper WO, Koepsell TD, et al. Provision of pneumococcal prophylaxis for publicly insured children with sickle cell disease. JAMA 2003; 290:1057.
[163] Zarkowsky HS, Gallagher D, Gill FM, et al. Bacteremia in sickle hemoglobinopathies. J Pediatr 1986; 109:579.
[164] Buchanan GR, Smith SJ, Holtkamp CA, Fuseler JP. Bacterial infection and splenic reticuloendothelial function in children with hemoglobin SC disease. Pediatrics 1983; 72:93.
[165] Rogers ZR, Buchanan GR. Bacteremia in children with sickle hemoglobin C disease and sickle beta(+)-thalassemia: is prophylactic penicillin necessary? J Pediatr 1995; 127:348.
[166] Lane PA, O’'Connell JL, Lear JL, et al. Functional asplenia in hemoglobin SC disease. Blood 1995; 85:2238.
[167] Lane PA, Rogers ZR, Woods GM, et al. Fatal pneumococcal septicemia in hemoglobin SC disease. J Pediatr 1994; 124:859.
[168] Morris C, Vichinsky E, Styles L. Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: is it accurate enough? Ann Emerg Med 1999; 34:64.
[169] Kawchak DA, Schall JI, Zemel BS, et al. Adequacy of dietary intake declines with age in children with sickle cell disease. J Am Diet Assoc 2007; 107:843.
[170] Hyacinth HI, Gee BE, Hibbert JM. The Role of Nutrition in Sickle Cell Disease. Nutr Metab Insights 2010; 3:57.
[171] Phillips G, Tangney CC. Relationship of plasma alpha tocopherol to index of clinical severity in individuals with sickle cell anemia. Am J Hematol 1992; 41:227.
[172] Claster S, Wood JC, Noetzli L, et al. Nutritional deficiencies in iron overloaded patients with hemoglobinopathies. Am J Hematol 2009; 84:344.
[173] Arruda MM, Mecabo G, Rodrigues CA, et al. Antioxidant vitamins C and E supplementation increases markers of haemolysis in sickle cell anaemia patients: a randomized, double-blind, placebo-controlled trial. Br J Haematol 2013; 160:688.
[174] Pearson HA, Cobb WT; Folic Acid Studies in sickle cell FOLIC ACID STUDIES IN SICKLE-CELL ANEMIA. J Lab Clin Med 1964; 64:913.
[175] Rabb LM, Grandison Y, Mason K, et al. A trial of folate supplementation in children with homozygous sickle cell disease. Br J Haematol 1983; 54:589.
[176] Van der Dijs FP, Schnog JJ, Brouwer DA, et al. Elevated homocysteine levels indicate suboptimal folate status in pediatric sickle cell patients. Am J Hematol 1998; 59:192.
[177] Kennedy TS, Fung EB, Kawchak DA, et al. Red blood cell folate and serum vitamin B12 status in children with sickle cell disease. J Pediatr Hematol Oncol 2001; 23:165.
[178] Lal A, Fung EB, Pakbaz Z, et al. Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer 2006; 47:901.
[179] Osunkwo I, Hodgman EI, Cherry K, et al. Vitamin D deficiency and chronic pain in sickle cell disease. Br J Haematol 2011; 153:538.
[180] Osunkwo I, Ziegler TR, Alvarez J, et al. High dose vitamin D therapy for chronic pain in children and adolescents with sickle cell disease: results of a randomized double blind pilot study. Br J Haematol 2012; 159:211.
[181] Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med 1997; 102:171.
[182] DeBaun MR, Sarnaik SA, Rodeghier MJ, et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood 2012; 119:3684.
[183] Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339:5.
[184] Valadi N, Silva GS, Bowman LS, et al. Transcranial Doppler ultrasonography in adults with sickle cell disease. Neurology 2006; 67:572.
[185] Sampaio Silva G, Vicari P, Figueiredo MS, et al. Transcranial Doppler in adult patients with sickle cell disease. Cerebrovasc Dis 2006; 21:38.
[186] Cohen RT, Madadi A, Blinder MA, et al. Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease. Am J Hematol 2011; 86:756.
[187] Klings ES, Machado RF, Barst RJ, et al. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med 2014; 189:727.
[188] Liem RI, Young LT, Lay AS, et al. Reproducibility of tricuspid regurgitant jet velocity measurements in children and young adults with sickle cell disease undergoing screening for pulmonary hypertension. Am J Hematol 2010; 85:741.
[189] Aguilar CM, Neumayr LD, Eggleston BE, et al. Clinical evaluation of avascular necrosis in patients with sickle cell disease: Children's Hospital Oakland Hip Evaluation Scale--a modification of the Harris Hip Score. Arch Phys Med Rehabil 2005; 86:1369.
[190] Wolf RB, Saville BR, Roberts DO, et al. Factors associated with growth and blood pressure patterns in children with sickle cell anemia: Silent Cerebral Infarct Multi-Center Clinical Trial cohort. Am J Hematol 2015; 90:2.
[191] Zemel BS, Kawchak DA, Fung EB, et al. Effect of zinc supplementation on growth and body composition in children with sickle cell disease. Am J Clin Nutr 2002; 75:300.
[192] Harmatz P, Heyman MB, Cunningham J, et al. Effects of red blood cell transfusion on resting energy expenditure in adolescents with sickle cell anemia. J Pediatr Gastroenterol Nutr 1999; 29:127.
[193] Heyman MB, Vichinsky E, Katz R, et al. Growth retardation in sickle-cell disease treated by nutritional support. Lancet 1985; 1:903.
[194] Fung EB, Barden EM, Kawchak DA, et al. Effect of hydroxyurea therapy on resting energy expenditure in children with sickle cell disease. J Pediatr Hematol Oncol 2001; 23:604.
[195] Nunlee-Bland G, Rana SR, Houston-Yu PE, Odonkor W. Growth hormone deficiency in patients with sickle cell disease and growth failure. J Pediatr Endocrinol Metab 2004; 17:601.
[196] Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325:11.
[197] Rees DC, Olujohungbe AD, Parker NE, et al. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol 2003; 120:744.
[198] Ballas SK. Treatment of pain in adults with sickle cell disease. Am J Hematol 1990; 34:49.
[199] Elander J, Lusher J, Bevan D, et al. Understanding the causes of problematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. J Pain Symptom Manage 2004; 27:156.
[200] Solomon LR. Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void. Blood 2008; 111:997.
[201] Darbari DS, Minniti CP, Rana S, van den Anker J. Pharmacogenetics of morphine: Potential implications in sickle cell disease. Am J Hematol 2008; 83:233.
[202] Sutton M, Atweh GF, Cashman TD, Davis WT. Resolving conflicts: misconceptions and myths in the care of the patient with sickle cell disease. Mt Sinai J Med 1999; 66:282.
[203] Tamayo-Sarver JH, Hinze SW, Cydulka RK, Baker DW. Racial and ethnic disparities in emergency department analgesic prescription. Am J Public Health 2003; 93:2067.
[204] Geller AK, O’Connor MK. The sickle cell crisis: a dilemma in pain relief. Mayo Clin Proc 2008; 83:320.
[205] Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA 2008; 299:70.
[206] Zempsky WT. Treatment of sickle cell pain: fostering trust and justice. JAMA 2009; 302:2479.
[207] The management of sickle cell disease. National Institutes of Health; National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources. NIH publication 04-2117, revised 2004. This reference is also available for downloading or purchase at:
health/prof/blood/sickle/ (Accessed on June 25, 2009).
[208] Ware MA, Hambleton I, Ochaya I, Serjeant GR. Day-care management of sickle cell painful crisis in Jamaica: a model applicable elsewhere? Br J Haematol 1999; 104:93.
[209] Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood 2000; 95:1130.
[210] Wright J, Bareford D, Wright C, et al. Day case management of sickle pain: 3 years' experience in a UK sickle cell unit. Br J Haematol 2004; 126:878.
[211] Frei-Jones MJ, Baxter AL, Rogers ZR, Buchanan GR. Vaso-occlusive episodes in older children with sickle cell disease: emergency department management and pain assessment. J Pediatr 2008; 152:281.
[212] Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med 2008; 148:94.
[213] Brookoff D, Polomano R. Treating sickle cell pain like cancer pain. Ann Intern Med 1992; 116:364.
[214] Lynch ME. A review of the use of methadone for the treatment of chronic noncancer pain. Pain Res Manag 2005; 10:133.
[215] Gagnon B, Almahrezi A, Schreier G. Methadone in the treatment of neuropathic pain. Pain Res Manag 2003; 8:149.
[216] Moulin D. Use of methadone for neuropathic pain. Pain Res Manag 2003; 8:131.
[217] Naik RP, Streiff MB, Lanzkron S. Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis 2013; 35:352.
[218] Brousse V, Elie C, Benkerrou M, et al. Acute splenic sequestration crisis in sickle cell disease: cohort study of 190 paediatric patients. Br J Haematol 2012; 156:643.
[219] Fernandes AP, Januário JN, Cangussu CB, et al. Mortality of children with sickle cell disease: a population study. J Pediatr (Rio J) 2010; 86:279.
[220] Pappo A, Buchanan GR. Acute splenic sequestration in a 2-month-old infant with sickle cell anemia. Pediatrics 1989; 84:578.
[221] Solanki DL, Kletter GG, Castro O. Acute splenic sequestration crises in adults with sickle cell disease. Am J Med 1986; 80:985.
[222] Orringer EP, Fowler VG Jr, Owens CM, et al. Case report: splenic infarction and acute splenic sequestration in adults with hemoglobin SC disease. Am J Med Sci 1991; 302:374.
[223] Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. Lancet 1998; 351:959.
[224] Adler BK, Salzman DE, Carabasi MH, et al. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 2001; 97:3313.
[225] Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. Blood 2001; 97:3998.
[226] Abboud MR, Taylor EC, Habib D, et al. Elevated serum and bronchoalveolar lavage fluid levels of interleukin 8 and granulocyte colony-stimulating factor associated with the acute chest syndrome in patients with sickle cell disease. Br J Haematol 2000; 111:482.
[227] Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.
[228] Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet 2001; 357:680.
[229] Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood 2004; 103:4023.
[230] Dampier C, LeBeau P, Rhee S, et al. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol 2011; 86:203.
[231] Serjeant GR, Higgs DR, Hambleton IR. Elderly survivors with homozygous sickle cell disease. N Engl J Med 2007; 356:642.
[232] Rees DC, Olujohungde AD, Parker NE et al. Guidelines for the Management of the Acute Painful Crisis in Sickle Cell Disease. British J of Haematology. 2003; 120: 744-752.
[233] Stewart M. Sickle Cell Disorder and Physiotherapy. Physiotherapy. 1997; 83: 333-339.
[234] Bernard TJ, Goldenberg NA, Armstrong WA et al. Treatment of Childhood Arterial Stroke. Annals of Neurology. 2008; 63: 679-696.
[235] Ingram VM (1989). A case of sickle-cell anaemia: a commentary on ‘Abnormal Human Hemoglobins. I. The Comparison of Normal Human and Sickle-Cell Hemoglobins by ‘Fingerprinting” with II. The Chymotryptic Digestion of the Trypsin-Resistant ‘Core’ of Hemoglobins A and S and III. The Chemical Difference Between Normal and Sickle Cell Hemoglobins. Biochim. Biophys. Acta 1000: 147-150.
[236] Campion MR (2000). Hidroterapia: Princípios e Prática. Manole, São Paulo.
[237] Tinti G, Somera R, Valente FM, Domingo CR. Benefits of kinesiotherapy and aquatic rehabilitation on sickle cell anemia: a case report. Genetics and Molecular Research. 2010; 9: 360-364.
[238] Ware JE Jr and Sherbourne CD (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30: 473-483.
[239] Graham C, Bond SS, Gerkovich MM and Cook MR (1980). Use of the McGill pain questionnaire in the assessment of cancer pain: replicability and consistency. Pain 8: 377-387.
[240] Goodman CC, Fuller KS. Pathology: Implications for the Physical Therapist. St. Louis; Saunders Elsevier: 2009.
[241] Millis, R M, Baker, F W, Ertugrul, I, Douglas, R M and Sexcius, L (1 994). ‘Physical performance decrements in children with sickle cell anaemia,’ Journal of the National Medical Association, 86, 2, 113-116.
[242] Alcorn, R, Bowser, 6, Henley, B J and Holloway, V (1984). ‘Fluidotherapy and exercise in the management of sickle cell anaemia,’ Physical Therapy, 64, 1520-22.
[243] Serjeant, G R (1 992). Sickle Cell Disease, Oxford University Press, 2nd edn. a - page 23, b - page 29, c - page 245, d - pages 246-251, e - page 258, f - page 190, g - page 295.
[244] Co, L I, Schmitz, T H, Havdala, H, Reyes, A and Westerman, M P (1979). Acupuncture: An evaluation in painful crisis,’ cited in Serjeant, G R (1992) op cit, pages 258-259.
[245] Wang, W C, George, S L and Williams, J A (1988). ‘Transcutaneous electrical nerve stimulation treatment of sickle cell pain crisis,’ cited in Sergeant, G R (1992) op cit, pages 258-259.
[246] Ohara DG, Ruas G, Castro SS, Martins PRJ, Walsh IA. Dorosteomuscular, perfil e qualidade de vida de indivíduos comdoenc¸a falciforme. Rev Bras Fisioter. 2012;16(5):431–8.9.
[247] Neumayr LD, Aguilar C, Earles AN, Jergesen HE, Haberkern CM, Kammen BF, et al. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a at a mean of three years after treatment. J Bone Joint Surg Am. 2006;88(12):2573–82.10.
[248] Barker AL, Talevski J, Morello RT, Brand CA, Rahmann AE,Urquhart DM. Effectiveness of aquatic exercise for musculoskeletal conditions: a meta-analysis. Arch Phys MedRehabil. 2014;95(9):1776–86.11.
[249] Becker BE. Aquatic therapy: scientific foundations and clinical rehabilitation applications. PM R. 2009;1(9):859–72.12.
[250] Poyhonen T, Sipila S, Keskinen KL, Hautala A, Savolainen J,Malkia E. Effects of aquatic resistance training on neuromuscular performance in healthy women. Med SciSports Exerc. 2002;34(12):2103–9.
[251] Sylvester KP, Patey RA, Milligan P, et al. Pulmonary function abnormalities in children with sickle cell disease. Thorax. 2004;59:67–70.
[252] Ahmed, S., Siddiqui, A.K. Pulmonary manifestations of sickle cell disease Postgrad Med J 2003;79:384-390.
[253] Powars D, Weidman JA, Odom-Maryon T, et al. Sickle cell chronic lung disease: prior morbidity and risk of pulmonary failure. Medicine, 1988;67:66–76.
[254] Klings ES, Wyszynski DF, Nolan VG, Steinberg MH. Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit Care Med. 2006; 173:1264–1269.
[255] Mak V, Davies SC. 2003. The pulmonary physician in critical care illustrative case 6: Acute chest syndrome of sickle cell anemia. Thorax 58:726-8.
[256] Sibinga EM, Shindell DL, Casella JF, Duggan AK, Wilson MH. Pediatric patients with sickle cell disease: use of complementary and alternative therapies. J Altern Complement Med. 2006;12:291–298.
[257] Stuart MJ, Nagel RL. 2004. Sickle-cell disease. Lancet 364:1343-60.
[258] Craven JL, Evans GA, Davenport PJ, Williams RHP. The evaluation of the incentive spirometer in the management of postoperative pulmonary complications. Br J Surg 1974;61:793-797.
[259] Krastins IRB, Corey ML, McLeod A, Edmonds J, Levison H, Moes F. An evaluation of incentive spirometry in the management of pulmonary complications after cardiac surgery in a pediatric population. Crit Care Med 1982;10:525-528.
[260] Hebbel RP, Boogaerts MAB, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle-cell anemia: a possible determinant of disease severity. N Engl J Med 1980;302:992-995.
[261] Fabry ME, Rajanayagam V, Fine E, et al. Modeling sickle cell vasoocclusion in the rat leg: quantification of trapped sickle cells and correlation with 31P metabolic and 1H magnetic resonance imaging changes. Proc Natl Acad Sci USA 1989;86:3808-3812.
[262] Morris CL, Rucknagel DL, Joiner CH. Deoxygenationinduced changes in sickle cell-sickle cell adhesion. Blood 1993;81:3138-3145.
[263] Bellet PS, Kalinyak KA, Rucknagel DL. Incentive Spirometry in Sickle Cell Crisis, N Engl J Med 1996; 334:124-127.
[264] Paul S. Bellet, Karen A. Kalinyak, Rakesh Shukla, Michael J. Gelfand, M.D., and Donald L. Rucknagel, M.D., Incentive Spirometry to Prevent Acute Pulmonary Complications in Sickle Cell Diseases. N Engl J Med 1995; 333:699-703.
[265] Ahmad FA, Macias CG, Allen JY; The use of incentive spirometry in pediatric patients with sickle cell disease to reduce the incidence of acute chest syndrome. J Pediatr Hematol Oncol. 2011 Aug;33(6):415-20.
[266] Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease -- life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
[267] Saminu KS, Adeniyiv AF; Local incentive spirometry improves peak expiratory flow rate in teenage sickle cell anaemia patients: a randomized pilot trial, Afr Health Sci. 2011 September; 11(3): 303–308.
[268] Amal A. Alotaibi, Intsar S. Waked. Beneficial effects of Incentive Spirometry on Pulmonary Problems in Patients with sickle cell Anemia, IJMRD, 2, (5), 53-58.
[269] Henley EJ: Engineering plus medicine equals Fluktotherapy. CHEMTECH 63:215-220, 1982.
[270] Roosevelt A, Barry B, Ernest J. Henley, and Viola Holloway; Fluidotherapy and Exercise in the Management of Sickle Cell Anemia, A Clinical Report, Volume 64, ( 10), 1984 1521-1522.
[271] Thompson, A, Skinner, A and Piercy, J (eds) ‘Diseases of the blood and lymph vessels, ulcers and scar tissue,’ Tidy’s Physiotherapy, Butterworth Heinemann, pages 276-283.

Audience: For both established researchers and graduate students who interested in genetics and physical therapy areas.

You have not viewed any product yet.